Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Ada Vaill
Institution:
Biohaven Pharmaceuticals (United States)
Observed institutions:
Biohaven Pharmaceuticals (United States),
AxioMx (United States)
OpenAlex ID:
A5075100716
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
2021
·
Takuya Tada
, Belinda M. Dcosta
, et al.
·
mBio
·
160
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
2021
·
Takuya Tada
, Belinda M. Dcosta
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
64
PDF
Use of micro-emulsion technology for the directed evolution of antibodies
2012
·
Diane L. Buhr
, Felicity E. Acca
, et al.
·
Methods
·
13
A first-in-class ex vivo combination between cytokine-induced memory like (CIML) NK cells and a CD38 targeting antibody recruiting molecule (ARM) as a novel approach to target NK cells without cellular engineering for the treatment of multiple myeloma.
2020
·
Luca Rastelli
, Maqbool Mohsin
, et al.
·
Journal of Clinical Oncology
·
1
KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab
2020
·
Christian Vidal
, Michael Cukan
, et al.
·
Blood
635 A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders
2020
·
Christian Vidal
, Michael Cukan
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
6
Citation count:
238
H-index:
3
I10-index:
3
Year
Topic
Type